- For Print
- October 10, 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting updates regarding its in-house discovered Lenvima®/Kisplyx® (lenvatinib mesylate, “lenvatinib”, selective inhibitor of receptor tyrosine kinases with a novel binding mode) and Halaven® (eribulin mesylate, “eribulin”, halichondrin class microtubule dynamics inhibitor) will be presented during the European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany, from October 19 to 23, 2018.
At the ESMO 2018 Congress, there will be an oral presentation on tumor growth rate prior to treatment administration and efficacy of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
A total of five poster presentations are scheduled to be given, consisting of two presentations for lenvatinib, including the results of correlative analyses of serum biomarkers and efficiency outcomes for lenvatinib, everolimus and the combination of these two agents in metastatic renal cell carcinoma, and three presentations for eribulin.
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
Oral Presentation:
*You can scroll to the left or right here
| Product | Abstract title and scheduled presentation date and time (local time) |
|---|---|
| Lenvatinib
Abstract No: 1819O |
Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer Oral Presentation | October 22 (Monday), 15:09-15:21 |
Major Poster Presentations:
*You can scroll to the left or right here
| Product | Abstract title and scheduled presentation date and time (local time) |
|---|---|
| Lenvatinib
Abstract No: 76P |
Correlative analyses of serum biomarkers and efficacy outcomes in the randomized, phase 2 trial of lenvatinib (LEN), everolimus (EVE) or LEN+EVE in patients with metastatic renal cell carcinoma Poster Presentation | October 20 (Sat), 12:30-13:30 |
|
Lenvatinib Abstract No: 59PD |
Final analysis of serum biomarkers in patients from the phase 3 study of lenvatinib vs sorafenib in unresectable hepatocellular carcinoma [REFLECT] Poster Presentation | October 20 (Sat), 15:00-16:00
|
|
Eribulin
|
Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: a real-world prospective study Poster Presentation | October 22 (Mon), 12:45-13:45 |
|
Eribulin
|
Early Results from an Open-label Phase 1b/2 Study of Eribulin Mesylate (EM) + Pegvorhyaluronidase Alfa (PEGPH20) Combination for the Treatment of Patients (Pts) with HER2-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) Poster Presentation | October 22 (Mon), 12:45-13:45 |
|
Eribulin
|
Economic Evaluation of Eribulin in the Treatment of Triple Negative Breast Cancer in the United Kingdom Poster Presentation | October 22 (Mon), 12:45-13:45 |
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
1. About LENVIMA®/KISPLYX® (lenvatinib mesylate)
Discovered and developed in-house by Eisai, LENVIMA is an orally administered kinase inhibitor with a novel binding mode that selectively inhibits the multi activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRα; KIT; and RET) involved in tumor angiogenesis, tumor progression and modification of tumor immunity.
Currently, Eisai has obtained approval for LENVIMA as a treatment for refractory thyroid cancer in over 50 countries, including the United States, Japan, in Europe. Additionally, Eisai has obtained approval for the agent in combination with everolimus as a second-line treatment for renal cell carcinoma in over 45 countries, including the United States and in Europe. In Europe, the agent was launched under the brand name KISPLYX® for renal cell carcinoma.
In addition, LENVIMA has been approved as a treatment for hepatocellular carcinoma in Japan, the United States, Europe, China and other countries. Eisai has submitted applications for an indication covering hepatocellular carcinoma in Taiwan (December 2017), as well as in other countries.
2. About the Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Strategic Collaboration
In March 2018, Eisai and Merck & Co., Inc. Kenilworth N.J., U.S.A., known as MSD outside of the U.S. and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc. Kenilworth N.J., U.S.A.’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab). In addition to ongoing clinical studies of the combination, the companies will jointly initiate new clinical studies evaluating the LENVIMA and KEYTRUDA combination to support 11 potential indications in six types of cancer, as well as a basket trial targeting multiple cancer types. The LENVIMA and KEYTRUDA combination is not approved in any cancer types today.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.